» Articles » PMID: 26674411

Targeting the Indoleamine 2,3-dioxygenase Pathway in Cancer

Overview
Date 2015 Dec 18
PMID 26674411
Citations 161
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of tryptophan depletion exerts an immunosuppressive effect, facilitating immune escape of tumors. This review summarizes our current knowledge on IDO expression in malignancies, the IDO inhibitors that are currently available and those under clinical development.

Citing Articles

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.

Hu Q, Shi Y, Wang H, Bing L, Xu Z Exp Hematol Oncol. 2025; 14(1):37.

PMID: 40087690 DOI: 10.1186/s40164-025-00627-6.


Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.

Demir T, Moloney C, Mahalingam D Cancers (Basel). 2025; 17(5).

PMID: 40075563 PMC: 11898821. DOI: 10.3390/cancers17050715.


Digital Health Technologies in Pediatric Infectious Disease and the Perspective of Patients and Healthcare Professionals: A Review.

Saji A, Komel A, Khan M, Niraula S, Naeem B, Ahsan A Health Sci Rep. 2025; 8(3):e70514.

PMID: 40041773 PMC: 11872690. DOI: 10.1002/hsr2.70514.


FAM64A regulates the malignant phenotype and tumor microenvironment of non-small cell lung cancer by activating the JAK/STAT3/PDL1 axis.

Shi S, Han J, Wu Q, Zhong H, Lei B, Yan Y J Mol Histol. 2025; 56(2):95.

PMID: 39992461 DOI: 10.1007/s10735-024-10339-6.


The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2).

Suvieri C, Belladonna M, Volpi C Cells. 2024; 13(22).

PMID: 39594642 PMC: 11593294. DOI: 10.3390/cells13221894.


References
1.
Munn D, Sharma M, Lee J, Jhaver K, Johnson T, Keskin D . Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002; 297(5588):1867-70. DOI: 10.1126/science.1073514. View

2.
Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

3.
Manches O, Munn D, Fallahi A, Lifson J, Chaperot L, Plumas J . HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest. 2008; 118(10):3431-9. PMC: 2528911. DOI: 10.1172/JCI34823. View

4.
Koblish H, Hansbury M, Bowman K, Yang G, Neilan C, Haley P . Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 2010; 9(2):489-98. DOI: 10.1158/1535-7163.MCT-09-0628. View

5.
Eguchi N, Watanabe Y, Kawanishi K, Hashimoto Y, HAYAISHI O . Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives. Arch Biochem Biophys. 1984; 232(2):602-9. DOI: 10.1016/0003-9861(84)90579-4. View